PHASE 1-2 STUDY INVESTIGATING SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF ANTI-PD-L1 MONOCLONAL ANTIBODY BGB-A333 ALONE AND IN COMBINATION WITH ANTI-PD-1 MONOCLONAL ANTIBODY TISLELIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
2018-000265-37EL ANTICUERPO MONOCLONAL ANTI-PD-L1 BGB-A333 EN MONOTERAPIAFundación Jiménez DíazInvestigador: MORENO GARCIA VICTOR
